Modern immunterapi i kombination med regional cancer behandling för patienter med malignt melanom - ett translationellt forskningsprojekt inkluderandes två kliniska studier

Immunotherapy have revolutionized the treatment of metastatic melanoma, however there is still an unmet need for effective treatments for specific patients grous, where immunotherapy has not shown effect.

We have previously shown that regional treatments can activate the immune-system and make these tumours more sensitive to immunotherapy.

The over-arching aim of this proposal is to further explore these findings and in two clinical trials combine regional treatments with immunotherapy to improve patient outcome, and pair this with extensive translational research.

The specific aims are:To evaluate in a clinical trial (SCANDIUM II trial) the combination of isolated hepatic perfusion (IHP) together with the checkpoint inhibitors ipilimumab and nivolumabTo determine in a clinical trial (Nivo-ILP trial) whether isolated limb perfusion (ILP) in combination with the checkpoint inhibitor nivolumab can increase efficacyTo identify predictive factors for response after by analysing immunological effects using FACS analysis and advanced multicolour microscopy.To sequence metastasis and analyze predictive factors for response and survival.Sahlgrenska University Hospital will act as sponsor for the clinical trials and the laboratory work will be performed at Sahlgrenska Cancer Center.

The SCANDIUM II trial is planned to start in Q1 2021 and the Nivo-ILP trial has already started in Q2 2020.